Thyroid eye disease (TED) is a debilitating autoimmune condition often associated with Graves disease that is characterized by inflammation and tissue remodeling in the orbit. This activity will review the clinical features of TED and methods for assessing clinical activity using the clinical activity score and explore the overlap between TED and dry eye disease to identify patients who may benefit from referral to a specialist. A comprehensive review of current management options will also be provided, including the introduction of teprotumumab, the first and only US Food and Drug Administration approved treatment for TED, to help clinicians learn how to select appropriate treatments across a spectrum of disease activity and duration and apply best practices for multidisciplinary management. This activity is designed for all clinicians involved in the care of patients with TED, including oculoplastic surgeons, ophthalmologists, and other eye care providers. The desired results of this activity are for clinicians treating TED to improve their ability to successfully manage this disease across broad clinical scenarios.
- Provider:MedEdicus, LLC
- Activity Link: https://courses.mededicus.com/
- Start Date: 2025-04-15 05:00:00
- End Date: 2025-04-15 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: Amgen, Inc. - Amount: 135400.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Limited